Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-03
  • 2025-02
  • 2025-01
  • 2024-12
  • 2024-11
  • 2024-10
  • 2024-09
  • 2024-08
  • 2024-07
  • 2024-06
  • 2024-05
  • 2024-04
  • 2024-03
  • 2024-02
  • 2024-01
  • 2023-12
  • 2023-11
  • 2023-10
  • 2023-09
  • 2023-08
  • 2023-07
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01
  • EZ Cap™ Cy5 Firefly Luciferase mRNA (5-moUTP): Cap1-Cappe...

    2025-11-05

    EZ Cap™ Cy5 Firefly Luciferase mRNA (5-moUTP): Cap1-Capped, Fluorescently Labeled Reporter for Reliable Mammalian Expression

    Executive Summary: EZ Cap™ Cy5 Firefly Luciferase mRNA (5-moUTP), also known as FLuc mRNA R1010, is a chemically modified messenger RNA optimized for mammalian systems. Its Cap1 structure and 5-methoxyuridine triphosphate (5-moUTP) modification reduce innate immune activation and enhance translation efficiency (Maniyamgama et al., 2024). Cy5 labeling enables dual-mode detection via fluorescence (excitation/emission: 650/670 nm) and bioluminescence (~560 nm). A poly(A) tail further stabilizes the mRNA. This construct is validated for mRNA delivery, translation efficiency assays, and in vivo imaging, with documented resistance to RNase degradation and compatibility with advanced delivery vehicles in buffered conditions (1 mM sodium citrate, pH 6.4, stored at -40°C or below).

    Biological Rationale

    Cap1-capped mRNAs more closely mimic endogenous mammalian transcripts than Cap0 mRNAs, leading to improved translation and reduced recognition by innate immune sensors such as RIG-I (Maniyamgama et al., 2024). Incorporation of 5-moUTP further suppresses innate immunity by decreasing uridine-driven Toll-like receptor (TLR) activation. The encoded enzyme, firefly Photinus pyralis luciferase, catalyzes ATP-dependent oxidation of D-luciferin, producing a quantifiable chemiluminescent signal (~560 nm). Cy5-UTP labeling allows for direct fluorescence tracking without compromising translation efficiency, as shown in dual-labeled mRNA applications (see related article). The poly(A) tail enhances transcript stability and facilitates ribosome recruitment. Together, these features make EZ Cap™ Cy5 Firefly Luciferase mRNA (5-moUTP) a benchmark tool for quantitative studies of mRNA delivery and expression in mammalian systems.

    Mechanism of Action of EZ Cap™ Cy5 Firefly Luciferase mRNA (5-moUTP)

    This mRNA is synthesized with a Cap1 structure via enzymatic capping using Vaccinia virus Capping Enzyme (VCE), GTP, S-adenosylmethionine (SAM), and 2'-O-Methyltransferase. Cap1 capping includes a methyl group at the 2'-O position of the first nucleotide, which increases translation efficiency and makes the mRNA less immunogenic in mammalian cells compared to Cap0 (Maniyamgama et al., 2024). During in vitro transcription, a 3:1 ratio of 5-moUTP to Cy5-UTP is incorporated, providing fluorescent labeling while maintaining coding capacity. The mRNA encodes firefly luciferase, enabling ATP-dependent chemiluminescence. The poly(A) tail is added post-transcriptionally to enhance stability and translation. When delivered into mammalian cells—such as via lipid nanoparticles or electroporation—the mRNA is translated, and reporter activity can be assayed by luminescence or Cy5 fluorescence. The combination of chemical modifications and capping results in improved in vivo performance, as demonstrated in mucosal and systemic delivery models.

    Evidence & Benchmarks

    • Cap1-capped and 5-moUTP-modified mRNAs show significantly reduced innate immune activation compared to unmodified mRNAs in mammalian cells, verified by reduced interferon-stimulated gene expression (Maniyamgama et al., 2024).
    • Cy5-labeled mRNAs maintain >90% translation efficiency relative to unlabeled controls in vitro, ensuring that labeling does not compromise protein output (EZ Cap™ Cy5 Firefly Luciferase mRNA: Fluorescent... ).
    • Poly(A) tails of >100 nt on synthetic mRNAs confer enhanced stability and translation in mammalian cells (Maniyamgama et al., 2024).
    • Intranasal delivery of chemically modified, Cap1-capped mRNA formulations results in up to 60-fold higher reporter protein expression in murine nasal tissue compared with standard LNP formulations (Maniyamgama et al., 2024).
    • Shipping on dry ice and storage at -40°C or below is required to maintain mRNA integrity and activity for at least 6 months (EZ Cap™ Cy5 Firefly Luciferase mRNA product page).

    This article extends prior coverage by explicitly benchmarking Cap1, 5-moUTP, and Cy5 modifications side-by-side (see previous review), and by integrating recent in vivo evidence on translation efficiency and immune evasion.

    Applications, Limits & Misconceptions

    EZ Cap™ Cy5 Firefly Luciferase mRNA (5-moUTP) is used in research applications including:

    • mRNA delivery and transfection optimization – as a gold-standard reporter for quantifying delivery vehicle efficacy.
    • Translation efficiency assays – in cell lines and primary cells, using luminescence and fluorescence readouts.
    • In vivo bioluminescence imaging – for noninvasive monitoring of expression kinetics in animal models.
    • Innate immune activation suppression studies – to model immune-quiet mRNA therapies.
    • Cell viability and cytotoxicity assessments – by correlating reporter activity with cell health.

    For a broader strategic discussion of translational research and mechanistic innovation, see this thought-leadership article, which this article updates with quantitative benchmarks for Cap1 and 5-moUTP modifications.

    Common Pitfalls or Misconceptions

    • Not suitable for direct therapeutic use. This product is for research only and is not GMP-grade.
    • Fluorescence signal may not reflect translation. Cy5 fluorescence indicates mRNA presence, not protein output.
    • Cap1 and 5-moUTP reduce, but do not eliminate, innate immune sensing. Residual immune responses may occur in some cell types.
    • Product must be protected from RNase contamination at all stages. Degradation will abolish both signals.
    • Cy5 labeling may interfere with downstream applications requiring unmodified nucleotides. Validation is needed for custom protocols.

    Workflow Integration & Parameters

    EZ Cap™ Cy5 Firefly Luciferase mRNA (5-moUTP) is supplied at ~1 mg/mL in 1 mM sodium citrate buffer (pH 6.4). Store at -40°C or below; avoid repeated freeze-thaw cycles. Handle on ice and use RNase-free materials. Recommended transfection protocols include lipid nanoparticle (LNP) delivery, electroporation, or microinjection. Optimal cell seeding density, reagent:mRNA ratio, and incubation times should be determined empirically for each cell line. For in vivo applications, validated dosing ranges from 0.1–10 µg per injection (mouse), depending on route and target tissue (Maniyamgama et al., 2024). Quantify expression via luminescence (luciferase substrate, 560 nm) and Cy5 fluorescence (excitation 650 nm/emission 670 nm). For troubleshooting and advanced workflows, see this recent update, which this article complements by providing structured integration parameters and highlighting storage/buffer conditions.

    Conclusion & Outlook

    EZ Cap™ Cy5 Firefly Luciferase mRNA (5-moUTP) sets a new standard for quantitative, immune-quiet, and dual-mode reporter assays in mammalian expression systems. Its Cap1 capping, 5-moUTP modification, and Cy5 labeling enable robust translation, low immunogenicity, and straightforward detection. Ongoing advances in LNP-mediated delivery and tissue-specific targeting are expected to further increase the utility of such constructs for preclinical research and translational development. For detailed specifications and ordering, visit the EZ Cap™ Cy5 Firefly Luciferase mRNA (5-moUTP) product page.